CSPCY: AI 评分 48/100 — AI 分析 (4月 2026)

CSPC Pharmaceutical Group Limited researches, develops, manufactures, and sells pharmaceutical products globally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments, offering a diverse portfolio of medications and healthcare products.

Key Facts: AI Score: 48/100 Sector: Healthcare

公司概况

概要：

CSPC Pharmaceutical Group Limited is a diversified pharmaceutical company focused on developing and marketing innovative drugs across multiple therapeutic areas, including oncology, cardiovascular, and neurology, primarily in China and expanding internationally, with a current P/E ratio of 21.25 and a dividend yield of 2.79%.

CSPCY是做什么的？

CSPC Pharmaceutical Group Limited, originally named China Pharmaceutical Group Limited until its rebranding in March 2013, was incorporated in 1992 and is headquartered in Shijiazhuang, China. The company operates as an investment holding entity with a core focus on the research, development, manufacture, and sale of pharmaceutical products. Its operations are segmented into Finished Drugs, Bulk Products, and Functional Food and Others. The company's finished drug portfolio includes treatments for acute ischemic stroke (NBP soft capsules and injections), memory impairment (Oulaining), Parkinson's disease (Enxi), various cancers (Duomeisu, Keaili), and chemotherapy-induced leucopenia (Jinyouli). Additionally, CSPC offers medications for infections (Shuluoke, Nuomoling, Weihong, Xinweihong), hypertension (Xuanning), atherosclerotic thrombosis (Encun), upper respiratory tract infections (Qixiao), diabetes (Linmeixin, Shuanglexin), osteoporosis (Gubang, Gubangjia), and various pain conditions (Gaoshunsong, Qimaite). Beyond pharmaceuticals, CSPC also produces bulk products like antibiotics, vitamin C, and caffeine APIs, as well as functional foods, glucose products, and healthcare services. The company's geographic reach extends across the People's Republic of China, other Asian regions, the Americas, and Europe.

CSPCY的投资论点是什么？

CSPC Pharmaceutical Group Limited presents a compelling investment case based on its diversified product portfolio and strong presence in the Chinese pharmaceutical market. With a market capitalization of $12.37 billion and a profit margin of 14.9%, the company demonstrates financial stability. Growth catalysts include the expansion of its innovative drug pipeline and increasing demand for healthcare products in China. The company's beta of 0.89 suggests lower volatility compared to the market. Key value drivers include successful commercialization of new drugs and strategic partnerships to expand its international footprint. Investors should monitor regulatory changes in China and potential competition from generic drug manufacturers.

CSPCY在哪个行业运营？

CSPC Pharmaceutical Group Limited operates within the global pharmaceutical industry, which is characterized by increasing demand for innovative drugs and healthcare solutions. The Chinese pharmaceutical market, in particular, is experiencing rapid growth due to an aging population and increasing healthcare spending. CSPC competes with both domestic and international pharmaceutical companies, including generic drug manufacturers and innovative drug developers. The industry is subject to stringent regulatory requirements and pricing pressures, which can impact profitability. Market trends include a growing focus on personalized medicine and the development of biosimilars.

Drug Manufacturers - General

Healthcare

CSPCY有哪些增长机遇？

Expansion of Innovative Drug Pipeline: CSPC has a significant opportunity to drive growth through the development and commercialization of innovative drugs targeting unmet medical needs. The company's research and development efforts in areas such as oncology and neurology could lead to breakthrough therapies with high market potential. Successful clinical trials and regulatory approvals could significantly boost revenue and market share, with potential revenues in the hundreds of millions annually per drug.
Strategic Partnerships and Acquisitions: CSPC can accelerate its growth by forming strategic partnerships with other pharmaceutical companies or acquiring promising drug candidates. Collaborations with international companies can facilitate access to new markets and technologies, while acquisitions can expand the company's product portfolio and pipeline. This approach could lead to substantial revenue synergies and cost savings, enhancing overall profitability within the next 3-5 years.
Increasing Healthcare Spending in China: The growing middle class and aging population in China are driving increased healthcare spending, creating a favorable environment for pharmaceutical companies like CSPC. The company can capitalize on this trend by expanding its sales and marketing efforts in China and offering affordable and accessible healthcare solutions. This demographic shift is expected to continue driving growth in the Chinese pharmaceutical market for the next decade.
International Expansion: CSPC has the opportunity to expand its geographic footprint beyond China and other Asian regions. By entering new markets in the Americas and Europe, the company can diversify its revenue streams and reduce its reliance on the Chinese market. This expansion could involve establishing local sales offices, partnering with distributors, or acquiring local pharmaceutical companies. The timeline for significant international revenue contribution is estimated at 5-7 years.
Focus on Functional Food and Healthcare Services: CSPC can leverage its existing infrastructure and expertise to expand its offerings in functional food and healthcare services. This diversification can provide additional revenue streams and reduce the company's dependence on pharmaceutical sales. The market for functional food and healthcare services is growing rapidly, driven by increasing consumer awareness of health and wellness. This expansion could contribute significantly to revenue growth within the next 2-3 years.

Market capitalization of $12.37 billion, reflecting significant investor confidence in the company's market position.
Profit margin of 14.9%, indicating efficient operations and strong profitability in the pharmaceutical sector.
Gross margin of 66.7%, showcasing the company's ability to maintain high profitability on its products.
Dividend yield of 2.79%, providing a steady income stream for investors.
Beta of 0.89, suggesting lower volatility compared to the overall market, making it a potentially stable investment.

CSPCY提供哪些产品和服务？

Researches and develops pharmaceutical products.
Manufactures a range of drugs, including those for stroke, memory impairment, and Parkinson's disease.
Sells pharmaceutical products in China, Asia, the Americas, and Europe.
Produces bulk products like antibiotics and vitamins.
Offers functional food and glucose products.
Provides healthcare services.

CSPCY如何赚钱？

Develops and manufactures pharmaceutical products.
Sells finished drugs through various distribution channels.
Generates revenue from bulk product sales.
Offers functional food and healthcare services for additional income.

Hospitals and clinics.
Pharmacies and drug stores.
Patients requiring prescription medications.
Consumers purchasing functional food and healthcare products.

Strong presence in the Chinese pharmaceutical market.
Diversified product portfolio across multiple therapeutic areas.
Established research and development capabilities.
Manufacturing expertise and infrastructure.

什么因素可能推动CSPCY股价上涨？

Upcoming: Potential regulatory approvals for new drug candidates in CSPC's pipeline.
Ongoing: Increasing demand for healthcare products in China due to an aging population.
Ongoing: Expansion of CSPC's sales and marketing efforts in international markets.
Upcoming: Strategic partnerships or acquisitions to expand product portfolio.
Ongoing: Continued investment in research and development of innovative therapies.

CSPCY的主要风险是什么？

Potential: Stringent regulatory requirements and pricing pressures in the pharmaceutical industry.
Potential: Competition from generic drug manufacturers and innovative drug developers.
Ongoing: Reliance on the Chinese market and exposure to regulatory changes in China.
Potential: Intellectual property risks and potential for patent infringement.
Potential: Currency fluctuations impacting the value of ADR investments.

CSPCY的核心优势是什么？

Diversified product portfolio.
Strong presence in the Chinese market.
Established research and development capabilities.
Integrated manufacturing infrastructure.

CSPCY的劣势是什么？

Reliance on the Chinese market.
Exposure to regulatory changes in China.
Competition from generic drug manufacturers.
Potential pricing pressures.

CSPCY有哪些机遇？

Expansion into new therapeutic areas.
Strategic partnerships and acquisitions.
Increasing healthcare spending in China.
International expansion.

CSPCY面临哪些威胁？

Stringent regulatory requirements.
Pricing pressures from governments and insurers.
Competition from domestic and international players.
Intellectual property risks.

CSPCY的竞争对手是谁？

Bayer AG — Multinational pharmaceutical and life sciences company. — (BDULF)
Bayer AG — Global competitor with a wide range of healthcare products. — (BDUUF)
Bayer AG — Diversified healthcare portfolio. — (BDUUY)
BioVie Inc. — Focuses on developing innovative therapies. — (BIOVF)
Erytech Pharma SA — Specializes in enzyme therapies. — (ERFSF)

Key Metrics

MoonshotScore: 48/100

Company Profile

CEO: Lei Cai
Headquarters: Shijiazhuang, CN
Employees: 21,400
Founded: 2021

AI Insight

AI analysis pending for CSPCY

ADR Level: 1
ADR Ratio: 1:1
Home Market Ticker: CSPC

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does CSPC Pharmaceutical Group Limited do?

CSPC Pharmaceutical Group Limited is a pharmaceutical company engaged in the research, development, manufacturing, and sale of pharmaceutical products. The company operates through three segments: Finished Drugs, Bulk Products, and Functional Food and Others. Its product portfolio includes treatments for various diseases, including stroke, memory impairment, Parkinson's disease, cancer, infections, hypertension, diabetes, and osteoporosis. CSPC also produces bulk products like antibiotics and vitamins, as well as functional food and healthcare services, primarily serving the Chinese market and expanding internationally.

What do analysts say about CSPCY stock?

Analyst consensus on CSPCY stock is currently pending. Key valuation metrics include a P/E ratio of 21.25 and a dividend yield of 2.79%. Growth considerations include the company's expansion of its innovative drug pipeline, increasing healthcare spending in China, and potential international expansion. Investors should monitor regulatory changes in China and potential competition from generic drug manufacturers. No buy or sell recommendations are made here.

What are the main risks for CSPCY?

The main risks for CSPCY include stringent regulatory requirements and pricing pressures in the pharmaceutical industry, competition from generic drug manufacturers and innovative drug developers, reliance on the Chinese market and exposure to regulatory changes in China, intellectual property risks and potential for patent infringement, and currency fluctuations impacting the value of ADR investments. These risks could impact the company's profitability and growth prospects.